Back to EZorb Newsletter Index

In this issue:

1. Share Success: Letters From Readers
2. Research News: Significant Weight Change May Indicate Increased Cardiovascular Risk in Type 2 Diabetes
3. Useful Links
4. What Are Others Saying About EZorb and Marvlix?

Letter I: From Tammy G.
Received at Testimonial Submit Form Wednesday, February 2, 2022 at 17:08:21
(Unedited)

Hi, my name is Tammy.

I've had problems in my knees for many years. My bedroom is upstairs. Walking the stairs is always a struggle.

My husband and I have been looking for a single-story home on and off for years. We thought we were in no rush...as a result we missed many opportunities to make the move. With the current housing market, we gave up. There's just no way anybody would accept our contingency offer.

A year ago, the arthritis in my left knee got really bad. I couldn't walk. The pain was unbearable. I cried every day.

Doctors insisted I need knee replacement. I'm only 62 and I heard horrible stories about joint replacement surgeries gone wrong.

I started researching online and found EZorb. I'd never heard of it but after reading about it for several days I decided to give it a try. This would be my last chance to avoid the replacement.

I bought 6 bottles and started taking 4 capsules twice a day. I noticed some pain relief in just a week but when the following week came it went back to my "normal" level of pain. I emailed Elixir and was told it would take on average 4-8 weeks to see significant improvement.

Then I got busy and distracted when my daughter and two grandsons moved in with us. One morning when I reached out to my EZorb bottle and realized that was my last of the 6 bottles I'd purchased. All a sudden I realized I haven't had much pain for quite a while.

I told my husband and he said he noticed I had no problem getting up and down the stairs.

So that was about 7 or 8 months ago. I'm on maintenance now and take 3 pills twice a day. I have no pain in my knees and have no trouble getting around taking care of my family.

Thank you EZorb! you have a lifelong customer.

Letter II: From Norman C.
Received at Testimonial Submit Form Friday, February 25, 2022 at 09:12:35
(Unedited)

Hi, my name is Norman and I'm in my 50s. I was diagnosed of Chronic Kidney Disease 7 months ago and that's when I looked up Marvlix.

I have had type 2 diabetes for 10+ years. Diabetes runs in my family. I take my meds faithfully. I knew it could affect my kidneys eventually but it was still depressing to find out it actually happened.

I took 8 Marvlix a day as recommended by medical staff. Two months later my GFR test showed no change which was actually not bad because the previous 2 reports showed consistent decline.

Then my latest test results came in Yesterday and totally blew me away! GFR went from 51 to 64. That's incredible! I'm the sole breadearner in my family of 5 and I've been so worried and depressed and the Lord has shined his light on me. Hallelujah!

Thank you so much! Marvlix is a godsend. I'll never go without it!

Our newsletter reaches over 200,000 subscribers worldwide. Success stories you shared in the past have made a great impact on many people's life.

Please email your story to sharesuccess @ ezorbonline.com or simply post it to Testimonial Submit Form. Your personal information will never be revealed to the public.

The gain or loss of more than 5% bodyweight within a 2-year period is associated with an increased risk for major adverse cardiovascular events in people with type 2 diabetes, say researchers.

Hyung-Kwan Kim (Seoul National University Hospital, Republic of Korea) and colleagues used the Korean National Health Insurance Service database to identify 1,522,241 people (average age 56.3 years, 63.7% men) who had type 2 diabetes and no history of major cardiovascular disease events.

The majority of study participants lost or gained no more than 5% of their starting bodyweight over a 2 -year period between two health check-ups. But 8% gained 5-10% and 2% gained more than that, and 12% and 3% lost the corresponding amounts of weight. Baseline BMIs in these groups ranged from 22.7 kg/m2 in the group with the most weight loss to 26.2 kg/m2 in the group with the most weight gain.

As reported in Diabetes Care, the team found a U-shaped relationship between these previous bodyweight changes and cardiovascular outcomes during a median follow-up of 7 years.

The strongest associations were seen for heart failure risk, with adjusted incidence rates of 10.73, 7.95, 6.44, 7.00, and 8.77 per 1000 person-years for people who, respectively, lost more than 10% bodyweight, lost 5-10%, remained relatively stable, gained 5-10%, and gained more than 10%.

After accounting for confounders, the risk for heart failure was significantly increased for people with weight loss or gain of at least 5% relative to those with stable weight, with hazard ratios ranging from 1.13 to 1.41.

This pattern was also observed for myocardial infarction, ischemic stroke, and atrial fibrillation, with almost all associations being statistically significant.

Furthermore, the same pattern was present for all-cause mortality, with adjusted incidence rates of 19.04, 10.80, 7.35, 8.62, and 12.09 per 1000 person-years across the groups from more than 10% weight loss to more than 10% weight gain. The adjusted hazard ratios for mortality relative to people in the stable weight group ranged from 1.23 to 1.87.

The researchers speculate that weight loss could lead to frailty and an increased risk for hypoglycemic events via the reduction of lean mass, and note that bodyweight variability per se has been linked to an increased risk for cardiovascular events.

“Taken together, the longer-term association between weight loss and cardiovascular events in patients with type 2 diabetes is possibly more complicated than we have expected based only on simple metabolic profile improvement with relatively limited follow-up duration,” they write.

The study authors add that they could not distinguish between intentional and unintentional weight loss, the latter of which could relate to an underlying disease condition.

“Therefore, weight loss in patients with type 2 diabetes observed in the clinic might not necessarily reflect metabolic improvement,” says the team.

Original research was published in Diabetes Care 2022; doi:10.2337/dc21-2299.

EZorb - Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.

Back to EZorb Newsletter Index